{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T13:27:13Z","timestamp":1782307633107,"version":"3.54.5"},"reference-count":54,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T00:00:00Z","timestamp":1766966400000},"content-version":"vor","delay-in-days":119,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012513","name":"Biomedical Research Network Centre in Cardiovascular Diseases","doi-asserted-by":"publisher","award":["CB16\/11\/00385"],"award-info":[{"award-number":["CB16\/11\/00385"]}],"id":[{"id":"10.13039\/501100012513","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medicina Cl\u00ednica"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.medcli.2025.107031","type":"journal-article","created":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T05:20:11Z","timestamp":1748928011000},"page":"107031","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Quality of anticoagulation with vitamin K antagonists in Spain: A systematic review with meta-analysis of national registries"],"prefix":"10.1016","volume":"165","author":[{"given":"Jos\u00e9 Miguel","family":"Rivera-Caravaca","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danilo","family":"Menichelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Pastori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Soler-Espejo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Asunci\u00f3n","family":"Esteve-Pastor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Vivas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inmaculada","family":"Rold\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Anguita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9","family":"Luis Ferreiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"Rold\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Mar\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.medcli.2025.107031_bib0275","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1160\/TH16-11-0876","article-title":"Stroke prevention in atrial fibrillation: past, present and future. Comparing the guidelines and practical decision-making","volume":"117","author":"Lip","year":"2017","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.medcli.2025.107031_bib0280","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/jth.12041","article-title":"The patterns of anticoagulation control and the risk of stroke, bleeding and mortality in patients with non-valvular atrial fibrillation","volume":"11","author":"Van Den Ham","year":"2013","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.medcli.2025.107031_bib0285","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1093\/eurheartj\/ehae176","article-title":"2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)","volume":"45","author":"Van Gelder","year":"2024","journal-title":"Eur Heart J"},{"key":"10.1016\/j.medcli.2025.107031_bib0290","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.clinthera.2017.11.014","article-title":"Reduced time in therapeutic range and higher mortality in atrial fibrillation patients taking acenocoumarol","volume":"40","author":"Rivera-Caravaca","year":"2018","journal-title":"Clin Ther"},{"key":"10.1016\/j.medcli.2025.107031_bib0295","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.ahj.2018.03.004","article-title":"Time to therapeutic range (TtTR), anticoagulation control, and cardiovascular events in vitamin K antagonists-naive patients with atrial fibrillation","volume":"200","author":"Pastori","year":"2018","journal-title":"Am Heart J"},{"key":"10.1016\/j.medcli.2025.107031_bib0300","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1055\/s-0039-1692175","article-title":"Subtherapeutic anticoagulation control under treatment with vitamin K-antagonists \u2013 data from a specialized coagulation service","volume":"119","author":"Prochaska","year":"2019","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.medcli.2025.107031_bib0545","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.medcli.2017.07.025","article-title":"Adherence to recommendations of the Therapeutic Positioning Report about treatment with oral anticoagulants in elderly patients with atrial fibrillation. The ESPARTA study","volume":"151","author":"Su\u00e1rez Fern\u00e1ndez","year":"2018","journal-title":"Med Clin (Barc)"},{"key":"10.1016\/j.medcli.2025.107031_bib0305","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1055\/s-0038-1651587","article-title":"A method to determine the optimal intensity of oral anticoagulant therapy","volume":"69","author":"Rosendaal","year":"1993","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.medcli.2025.107031_bib0310","article-title":"Time in therapeutic range and percentage of international normalized ratio in the therapeutic range as a measure of quality of anticoagulation control in patients with atrial fibrillation","volume":"32","author":"Chan","year":"2016","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.medcli.2025.107031_bib0315","series-title":"The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses","author":"Wells","year":"2000"},{"key":"10.1016\/j.medcli.2025.107031_bib0320","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.jclinepi.2012.09.016","article-title":"Testing a tool for assessing the risk of bias for nonrandomized studies showed moderate reliability and promising validity","volume":"66","author":"Kim","year":"2013","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.medcli.2025.107031_bib0325","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/jrsm.1411","article-title":"Risk-of-bias VISualization (robvis): an R package and Shiny web app for visualizing risk-of-bias assessments","volume":"12","author":"McGuinness","year":"2021","journal-title":"Res Synth Methods"},{"key":"10.1016\/j.medcli.2025.107031_bib0330","series-title":"Cochrane handbook for systematic reviews of interventions","author":"Higgins","year":"2008"},{"key":"10.1016\/j.medcli.2025.107031_bib0335","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.recesp.2014.11.022","article-title":"Quality of vitamin K antagonist anticoagulation in Spain: prevalence of poor control and associated factors","volume":"68","author":"Anguita S\u00e1nchez","year":"2015","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"key":"10.1016\/j.medcli.2025.107031_bib0340","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.recesp.2015.04.017","article-title":"Anticoagulation control in patients with nonvalvular atrial fibrillation attended at primary care centers in Spain: the PAULA Study","volume":"68","author":"Barrios","year":"2015","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"key":"10.1016\/j.medcli.2025.107031_bib0350","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.rce.2018.04.020","article-title":"Factors associated with poor anticoagulation control with vitamin K antagonists among outpatients attended in Internal Medicine and Neurology. The ALADIN study","volume":"218","author":"Contreras Muruaga","year":"2018","journal-title":"Rev Clin Esp (Barc)"},{"key":"10.1016\/j.medcli.2025.107031_bib0355","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1093\/europace\/eux314","article-title":"Quality of oral anticoagulation with vitamin K antagonists in \u2018real-world\u2019 patients with atrial fibrillation: a report from the prospective multicentre FANTASIIA registry","volume":"20","author":"Esteve-Pastor","year":"2018","journal-title":"Europace"},{"key":"10.1016\/j.medcli.2025.107031_bib0360","first-page":"165","article-title":"ICUSI questionnaire validation. Quality of anticoagulation in patients with atrial fibrillation treated with vitamin K antagonists","volume":"54","author":"Benezet-Mazuecos","year":"2019","journal-title":"REC: CardioClinics"},{"key":"10.1016\/j.medcli.2025.107031_bib0365","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1093\/europace\/euab131","article-title":"Variables affecting the quality of anticoagulation in atrial fibrillation patients newly initiating vitamin K antagonists: insights from the national and multicentre SULTAN registry","volume":"24","author":"Rivera-Caravaca","year":"2022","journal-title":"Europace"},{"key":"10.1016\/j.medcli.2025.107031_bib0370","author":"Agencia-Espa\u00f1ola-del-Medicamento","year":"2024"},{"key":"10.1016\/j.medcli.2025.107031_bib0375","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1093\/europace\/eux301","article-title":"Contemporary stroke prevention strategies in 11096 European patients with atrial fibrillation: a report from the EURObservational Research Programme on Atrial Fibrillation (EORP-AF) Long-Term General Registry","volume":"20","author":"Boriani","year":"2018","journal-title":"Europace"},{"key":"10.1016\/j.medcli.2025.107031_bib0380","doi-asserted-by":"crossref","first-page":"e023907","DOI":"10.1161\/JAHA.121.023907","article-title":"Global oral anticoagulation use varies by region in patients with recent diagnosis of atrial fibrillation: the GLORIA-AF Phase III Registry","volume":"11","author":"Bayer","year":"2022","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.medcli.2025.107031_bib0385","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1002\/joa3.12588","article-title":"Changes in anticoagulant prescription patterns over time for patients with atrial fibrillation around the world","volume":"37","author":"Kozie\u0142","year":"2021","journal-title":"J Arrhythm"},{"key":"10.1016\/j.medcli.2025.107031_bib0390","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.recesp.2014.04.020","article-title":"Assessment of degree of anticoagulation control in patients with atrial fibrillation in primary health care in Galicia, Spain: ANFAGAL Study","volume":"68","author":"Cinza-Sanjurjo","year":"2015","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"key":"10.1016\/j.medcli.2025.107031_bib0395","doi-asserted-by":"crossref","first-page":"e0211681","DOI":"10.1371\/journal.pone.0211681","article-title":"Quality of INR control and switching to non-vitamin K oral anticoagulants between women and men with atrial fibrillation treated with vitamin K antagonists in Spain. A population-based, real-world study","volume":"14","author":"Garc\u00eda-Sempere","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.medcli.2025.107031_bib0400","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1177\/08971900241256779","article-title":"Changes in time in therapeutic range within a warfarin anticoagulation clinic following introduction of direct oral anticoagulants","volume":"37","author":"Samuel","year":"2024","journal-title":"J Pharm Pract"},{"key":"10.1016\/j.medcli.2025.107031_bib0405","doi-asserted-by":"crossref","first-page":"2866","DOI":"10.3390\/jcm10132866","article-title":"Many good reasons to switch from vitamin K antagonists to non-vitamin K antagonists in patients with non-valvular atrial fibrillation","volume":"10","author":"Botto","year":"2021","journal-title":"J Clin Med"},{"key":"10.1016\/j.medcli.2025.107031_bib0410","doi-asserted-by":"crossref","first-page":"e0181000","DOI":"10.1371\/journal.pone.0181000","article-title":"Non-vitamin K oral anticoagulants are non-inferior for stroke prevention but cause fewer major bleedings than well-managed warfarin: a retrospective register study","volume":"12","author":"Sj\u00f6gren","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.medcli.2025.107031_bib0415","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.thromres.2018.05.022","article-title":"Dabigatran, rivaroxaban and apixaban vs. high TTR warfarin in atrial fibrillation","volume":"167","author":"Sj\u00e4lander","year":"2018","journal-title":"Thromb Res"},{"key":"10.1016\/j.medcli.2025.107031_bib0420","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s11239-022-02763-w","article-title":"Reduced dose direct oral anticoagulants compared with warfarin with high time in therapeutic range in nonvalvular atrial fibrillation","volume":"55","author":"Jansson","year":"2023","journal-title":"J Thromb Thrombolysis"},{"key":"10.1016\/j.medcli.2025.107031_bib0425","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.amjcard.2020.10.064","article-title":"Meta-analysis of safety and efficacy of direct oral anticoagulants versus warfarin according to time in therapeutic range in atrial fibrillation","volume":"140","author":"Lee","year":"2021","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.medcli.2025.107031_bib0430","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1161\/CIRCOUTCOMES.108.796185","article-title":"Anticoagulation control and prediction of adverse events in patients with atrial fibrillation: a systematic review","volume":"1","author":"Wan","year":"2008","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.medcli.2025.107031_bib0435","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1016\/j.jacc.2018.06.065","article-title":"Outcomes among patients with atrial fibrillation and appropriate anticoagulation control","volume":"72","author":"Bonde","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.medcli.2025.107031_bib0440","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.ijcard.2015.08.054","article-title":"Inadequate anticoagulation by vitamin K antagonists is associated with major adverse cardiovascular events in patients with atrial fibrillation","volume":"201","author":"Pastori","year":"2015","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.medcli.2025.107031_bib0445","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.medcli.2021.12.004","article-title":"Characteristics and management of patients with stroke and major hemorrhagic episodes with atrial fibrillation under vitamin K antagonist therapy. EVENTHO study","volume":"159","author":"Gav\u00edn","year":"2022","journal-title":"Med Clin (Barc)"},{"key":"10.1016\/j.medcli.2025.107031_bib0450","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1001\/jamacardio.2016.0199","article-title":"Outcomes in a warfarin-treated population with atrial fibrillation","volume":"1","author":"Bj\u00f6rck","year":"2016","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.medcli.2025.107031_bib0455","doi-asserted-by":"crossref","first-page":"2364825","DOI":"10.1080\/07853890.2024.2364825","article-title":"Time-in-therapeutic-range defined warfarin and direct oral anticoagulants in atrial fibrillation: a Nationwide Cohort Study","volume":"56","author":"Lehto","year":"2024","journal-title":"Ann Med"},{"key":"10.1016\/j.medcli.2025.107031_bib0460","doi-asserted-by":"crossref","first-page":"132","DOI":"10.33963\/KP.a2022.0287","article-title":"Comparison of the real-life clinical outcomes of warfarin with effective time in therapeutic range and non-vitamin K antagonist oral anticoagulants: insight from the AFTER-2 trial","volume":"81","author":"Aktan","year":"2023","journal-title":"Kardiol Pol"},{"key":"10.1016\/j.medcli.2025.107031_bib0465","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/s40273-014-0246-7","article-title":"Cost effectiveness of novel oral anticoagulants for stroke prevention in atrial fibrillation depending on the quality of warfarin anticoagulation control","volume":"33","author":"Janzic","year":"2015","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.medcli.2025.107031_bib0470","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s40256-018-0279-y","article-title":"Comparing the cost effectiveness of non-vitamin K antagonist oral anticoagulants with well-managed warfarin for stroke prevention in atrial fibrillation patients at high risk of bleeding","volume":"18","author":"Hospodar","year":"2018","journal-title":"Am J Cardiovasc Drugs"},{"key":"10.1016\/j.medcli.2025.107031_bib0475","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1093\/europace\/euy262","article-title":"The importance of time in therapeutic range in switching from vitamin K antagonist to non-vitamin K antagonist oral anticoagulants in atrial fibrillation","volume":"21","author":"Vinding","year":"2019","journal-title":"Europace"},{"key":"10.1016\/j.medcli.2025.107031_bib0480","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1160\/TH13-06-0443","article-title":"Vitamin K antagonists in heart disease: current status and perspectives (section III). Position paper of the ESC Working Group on Thrombosis \u2013 Task Force on Anticoagulants in Heart Disease","volume":"110","author":"De Caterina","year":"2013","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.medcli.2025.107031_bib0485","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1111\/jth.14625","article-title":"Effect of multidose drug dispensing on the time in therapeutic range in patients using vitamin-K antagonists: a randomized controlled trial","volume":"18","author":"Mertens","year":"2020","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.medcli.2025.107031_bib0490","first-page":"1632","article-title":"Quality of warfarin therapy and quality of life are improved by self-management for two years","volume":"19","author":"S\u00f8lvik","year":"2019","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.medcli.2025.107031_bib0495","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1055\/s-0039-1692175","article-title":"Subtherapeutic anticoagulation control under treatment with vitamin K-antagonists \u2013 data from a specialized coagulation service","volume":"119","author":"Prochaska","year":"2019","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.medcli.2025.107031_bib0500","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1007\/s11239-019-02031-4","article-title":"Does telehealth improve anticoagulation management in patient service centers (PSC)? A pilot project","volume":"49","author":"Bernstein","year":"2020","journal-title":"J Thromb Thrombolysis"},{"key":"10.1016\/j.medcli.2025.107031_bib0505","doi-asserted-by":"crossref","first-page":"e0284425","DOI":"10.1371\/journal.pone.0284425","article-title":"Quality of anticoagulant control and patient experience associated with long-term warfarin in Canadian patients with non-valvular atrial fibrillation: a multicentre, prospective study","volume":"18","author":"Selby","year":"2023","journal-title":"PLoS One"},{"key":"10.1016\/j.medcli.2025.107031_bib0510","doi-asserted-by":"crossref","first-page":"605353","DOI":"10.3389\/fphar.2020.605353","article-title":"Anticoagulation quality of warfarin and the role of physician\u2013pharmacist collaborative clinics in the treatment of patients receiving warfarin: a retrospective, observational, single-center study","volume":"11","author":"Qiu","year":"2020","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.medcli.2025.107031_bib0515","doi-asserted-by":"crossref","DOI":"10.3390\/jpm12030487","article-title":"Relation of the \u2018Atrial Fibrillation Better Care (ABC) Pathway\u2019 to the quality of anticoagulation in atrial fibrillation patients taking vitamin K antagonists","volume":"12","author":"Rold\u00e1n","year":"2022","journal-title":"J Pers Med"},{"key":"10.1016\/j.medcli.2025.107031_bib0520","doi-asserted-by":"crossref","first-page":"e74037","DOI":"10.1371\/journal.pone.0074037","article-title":"Educational intervention improves anticoagulation control in atrial fibrillation patients: the TREAT randomised trial","volume":"8","author":"Clarkesmith","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.medcli.2025.107031_bib0525","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.ijcard.2005.07.031","article-title":"Patient knowledge and perceptions of atrial fibrillation and anticoagulant therapy: effects of an educational intervention programme. The West Birmingham Atrial Fibrillation Project","volume":"110","author":"Lane","year":"2006","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.medcli.2025.107031_bib0530","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s11239-022-02718-1","article-title":"Higher OAK (Oral Anticoagulation Knowledge) score at baseline associated with better TTR (Time in Therapeutic Range) in patients taking warfarin","volume":"55","author":"Feldeisen","year":"2023","journal-title":"J Thromb Thrombolysis"},{"key":"10.1016\/j.medcli.2025.107031_bib0535","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1111\/jth.15592","article-title":"Switching from vitamin K antagonists to direct oral anticoagulants in non-valvular atrial fibrillation patients: does low time in therapeutic range affect persistence?","volume":"20","author":"Toorop","year":"2022","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.medcli.2025.107031_bib0540","doi-asserted-by":"crossref","first-page":"e020904","DOI":"10.1161\/JAHA.121.020904","article-title":"Direct oral anticoagulant adherence of patients with atrial fibrillation transitioned from warfarin","volume":"10","author":"Pundi","year":"2021","journal-title":"J Am Heart Assoc"}],"container-title":["Medicina Cl\u00ednica"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025775325002593?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025775325002593?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T16:52:39Z","timestamp":1767113559000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025775325002593"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":54,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S0025775325002593"],"URL":"https:\/\/doi.org\/10.1016\/j.medcli.2025.107031","relation":{},"ISSN":["0025-7753"],"issn-type":[{"value":"0025-7753","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Quality of anticoagulation with vitamin K antagonists in Spain: A systematic review with meta-analysis of national registries","name":"articletitle","label":"Article Title"},{"value":"Medicina Cl\u00ednica","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.medcli.2025.107031","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}],"article-number":"107031"}}